Under Federal regulations, proposed phase I studies are evaluated almost exclusively for safety reasons. -Since the late 1980’s FDA reviewers have been instructed to provide drug sponsors with greater freedom during phase I In evaluating phase II and III investigation, FDA reviewers also must ensure that these studies are of sufficient scientific quality to be capable of yielding data that can support marketing approval